

DATE: July 1, 2019
TO: All Well Sense Health Plan Providers
FROM: Well Sense Health Plan
SUBJECT: **Pharmacy Benefit Updates**

Policy and Prior Authorization Program Changes

The following clinical policies have been updated; these changes are effective September 2, 2019:

- 9.099 Forteo/Prolia/Xgeva
- 9.131 Angiotensin Receptor Antagonists
- 9.164 Beta Blockers
- 9.121 Ranexa
- 9.41 Antineoplastic Agents
- 9.170 Multiple Sclerosis
- 9.114 Insomnia Medications / Wakefulness-promoting agents
- 9.031 Makena
- 9.100 Bisphosphonates*

*policy discontinued

The following drug(s) will move to step therapy requirement effective September 2, 2019:

- Risedronate
- Ibandronate Oral
- Candesartan
- Candesartan HCT
- Captopril
- Captopril HCT
- Propranolol ER
- Nadolol

The following drug(s) will require prior authorization under specific clinical pharmacy policies effective September 2, 2019:

- Diacomit
- Ranolazine ER
- Bravtofi
- Daurismo
- Bosulif 400mg
- Mektovi
- Talzenna
- Rozerem
- Doxepin Topical
- Tibsovo
- Mayzent
- Mavenclad
- Prudoxin Topical
- Zonalon Topical

Pharmacy Benefit Update



The following drug(s) will be **Non-Preferred** effective September 2, 2019:

- Amlodipine/valsartan HCT
- Ibandronate Inj

The following drug(s) will be **covered without a prior authorization** effective September 2, 2019:

- Zoledronic acid 5mg (Reclast)
- Glatopa 40mg
- Tasisign 50mg
- Olmesartan
- Olmesartan HCT

Please visit the **[Pharmacy section](#)** of wellsense.org for complete policies and forms. The updated policies will be available in the provider notification section of the Pharmacy page at **www.wellsense.org** by the first week of September.